MX2023014840A - Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. - Google Patents
Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos.Info
- Publication number
- MX2023014840A MX2023014840A MX2023014840A MX2023014840A MX2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- pathway
- combination
- metabolic disorders
- myostatin
- Prior art date
Links
- 230000037361 pathway Effects 0.000 title abstract 4
- 102000004472 Myostatin Human genes 0.000 title abstract 2
- 108010056852 Myostatin Proteins 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación se refiere al tratamiento de trastornos metabólicos, tales como el síndrome metabólico, la obesidad y la diabetes de tipo 2. Se desvelan terapias complementarias y terapias de combinación que incluyen un inhibidor de la vía de la miostatina, utilizado en conjunto con un activador de la vía del GLP-1.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214234P | 2021-06-23 | 2021-06-23 | |
| US202163260136P | 2021-08-10 | 2021-08-10 | |
| US202163260254P | 2021-08-13 | 2021-08-13 | |
| US202263266348P | 2022-01-03 | 2022-01-03 | |
| US202263269702P | 2022-03-21 | 2022-03-21 | |
| PCT/US2022/034588 WO2022271867A1 (en) | 2021-06-23 | 2022-06-22 | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014840A true MX2023014840A (es) | 2024-02-12 |
Family
ID=82608742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014840A MX2023014840A (es) | 2021-06-23 | 2022-06-22 | Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368262A1 (es) |
| EP (1) | EP4358995A1 (es) |
| JP (1) | JP2024524159A (es) |
| AU (1) | AU2022299185A1 (es) |
| CA (1) | CA3221555A1 (es) |
| IL (1) | IL309078A (es) |
| MX (1) | MX2023014840A (es) |
| TW (1) | TW202317175A (es) |
| WO (1) | WO2022271867A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024064842A1 (en) * | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| SI2981822T1 (sl) | 2013-05-06 | 2021-08-31 | Scholar Rock, Inc. | Sestavki in postopki za modulacijo rastnega dejavnika |
| CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| UA127961C2 (uk) | 2014-12-19 | 2024-02-28 | Чугей Сейяку Кабусікі Кайся | Антитіло до латентного міостатину |
| KR20230155021A (ko) | 2015-09-15 | 2023-11-09 | 스칼러 락, 인크. | 항-프로/잠재성-미오스타틴 항체 및 그의 용도 |
| EP3400240A2 (en) | 2016-01-08 | 2018-11-14 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
| JP6823167B2 (ja) | 2016-06-13 | 2021-01-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | ミオスタチン阻害剤の使用および併用療法 |
| JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| PT3565592T (pt) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
| US20210087250A1 (en) * | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| SG11202108099WA (en) * | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
-
2022
- 2022-06-22 MX MX2023014840A patent/MX2023014840A/es unknown
- 2022-06-22 CA CA3221555A patent/CA3221555A1/en active Pending
- 2022-06-22 JP JP2023578073A patent/JP2024524159A/ja active Pending
- 2022-06-22 IL IL309078A patent/IL309078A/en unknown
- 2022-06-22 US US18/572,397 patent/US20240368262A1/en active Pending
- 2022-06-22 AU AU2022299185A patent/AU2022299185A1/en active Pending
- 2022-06-22 WO PCT/US2022/034588 patent/WO2022271867A1/en active Application Filing
- 2022-06-22 EP EP22744054.2A patent/EP4358995A1/en active Pending
- 2022-06-23 TW TW111123506A patent/TW202317175A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358995A1 (en) | 2024-05-01 |
| JP2024524159A (ja) | 2024-07-05 |
| IL309078A (en) | 2024-02-01 |
| US20240368262A1 (en) | 2024-11-07 |
| CA3221555A1 (en) | 2022-12-29 |
| AU2022299185A1 (en) | 2024-01-25 |
| WO2022271867A1 (en) | 2022-12-29 |
| TW202317175A (zh) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| MX2019011221A (es) | Terapia de combinacion para el tratamiento o prevencion de tumores. | |
| EA201101191A1 (ru) | Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX342305B (es) | Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina. | |
| UA102669C2 (en) | Use of dpp-iv inhibitors | |
| ECSP066268A (es) | Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares | |
| MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
| PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| BRPI0514253A (pt) | terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8 | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2023014840A (es) | Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. | |
| MX2020010302A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| MX2024001155A (es) | Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r. | |
| HK1073250A1 (en) | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | |
| MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
| PH12021550741A1 (en) | Vibegron for the treatment of overactive bladder symptoms | |
| MX2021006540A (es) | Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). | |
| MX2022000783A (es) | Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales. | |
| EA201290485A1 (ru) | Производные бензамида | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
| RU2014152196A (ru) | Способ улучшения функции печени |